Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?

Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients? Breast Cancer Research and Treatment (2018) 168:283 https://doi.org/10.1007/s10549-017-4589-6 LE T TER TO  THE   EDITOR Does tacrolimus have any positive impact on outcome of post‑transplant breast cancer patients? Kadri Altundag Received: 26 October 2017 / Accepted: 22 November 2017 / Published online: 24 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 Acknowledgements The author has not received any grants. Dear Editor, Compliance with ethical standards I wish to congratulate Jeong and colleagues for their article [1] in which the characteristics and prognosis of post-trans- Conflict of interest I have no conflict of interest to declare. plant breast cancer (PTBC) patients receiving immunosup- pressants and general breast cancer patients were compared. Ethical approval My manuscript complies with the Ethical Rules appli- They reported that subtype and prognosis of breast cancer cable for this journal. were comparable with that in the general cohort and immu- Research involving human and animal participants This article does nosuppressants do not adversely affect breast cancer prog - not contain any studies with human participants or animals performed nosis. In this study, 24 were diagnosed with PTBC. Of the by the author. 24 PTBC cohort, 12 received mammalian target of rapa- mycin (mTOR) inhibitor—tacrolimus as immunosuppres- sive agent. Results of both the TAMRAD and BOLERO-2 References studies showed that mTOR inhibition in combination with endocrine therapy improved progression-free survival for 1. Jeong IJ, Lee SG, Kim YH, Ko BS, Lee JW, Son BH, Ahn SH, hormone receptor-positive metastatic breast cancer patients Kim HJ (2017) Characteristics and prognosis of breast cancer [2]. For this reason, it would be interesting to compare the after liver or kidney transplantation. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4504-1 outcome of hormone receptor-positive PTBC patients who 2. Sendur MA, Zengin N, Aksoy S, Altundag K (2014) Everolimus: received endocrine treatment and tacrolimus with hormone a new hope for patients with breast cancer. Curr Med Res Opin receptor-positive patients in general cohort. 30(1):75–87. https://doi.org/10.1185/03007995.2013.846253 * Kadri Altundag altundag66@yahoo.com MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey Vol.:(0123456789) 1 3 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/does-tacrolimus-have-any-positive-impact-on-outcome-of-post-transplant-XpAbNXuQGi
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4589-6
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Research and Treatment (2018) 168:283 https://doi.org/10.1007/s10549-017-4589-6 LE T TER TO  THE   EDITOR Does tacrolimus have any positive impact on outcome of post‑transplant breast cancer patients? Kadri Altundag Received: 26 October 2017 / Accepted: 22 November 2017 / Published online: 24 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 Acknowledgements The author has not received any grants. Dear Editor, Compliance with ethical standards I wish to congratulate Jeong and colleagues for their article [1] in which the characteristics and prognosis of post-trans- Conflict of interest I have no conflict of interest to declare. plant breast cancer (PTBC) patients receiving immunosup- pressants and general breast cancer patients were compared. Ethical approval My manuscript complies with the Ethical Rules appli- They reported that subtype and prognosis of breast cancer cable for this journal. were comparable with that in the general cohort and immu- Research involving human and animal participants This article does nosuppressants do not adversely affect breast cancer prog - not contain any studies with human participants or animals performed nosis. In this study, 24 were diagnosed with PTBC. Of the by the author. 24 PTBC cohort, 12 received mammalian target of rapa- mycin (mTOR) inhibitor—tacrolimus as immunosuppres- sive agent. Results of both the TAMRAD and BOLERO-2 References studies showed that mTOR inhibition in combination with endocrine therapy improved progression-free survival for 1. Jeong IJ, Lee SG, Kim YH, Ko BS, Lee JW, Son BH, Ahn SH, hormone receptor-positive metastatic breast cancer patients Kim HJ (2017) Characteristics and prognosis of breast cancer [2]. For this reason, it would be interesting to compare the after liver or kidney transplantation. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4504-1 outcome of hormone receptor-positive PTBC patients who 2. Sendur MA, Zengin N, Aksoy S, Altundag K (2014) Everolimus: received endocrine treatment and tacrolimus with hormone a new hope for patients with breast cancer. Curr Med Res Opin receptor-positive patients in general cohort. 30(1):75–87. https://doi.org/10.1185/03007995.2013.846253 * Kadri Altundag altundag66@yahoo.com MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey Vol.:(0123456789) 1 3

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Nov 24, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off